Funder
Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India
National Institute of Pharmaceutical Education and Research, Raebareli
Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference27 articles.
1. A unique CDK4/6 inhibitor: current and future therapeutic strategies of abemaciclib;Chong;Pharmacol. Res.,2020
2. Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes;Hino;Cancer Sci.,2020
3. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer;Corona;Drug Des., Dev. Ther.,2018
4. Update on metabolism of abemaciclib: In silico, in vitro, and in vivo metabolite identification and characterization using high resolution mass spectrometry;Thakkar;Drug Test. Anal.,2020
5. Forced degradation studies: regulatory guidance, characterization of drugs, and their degradation products-a review;Venkataraman;Drug Invent. Today,2018